(4-bromo-2-chlorophenyl)(pyrrolidin-1-yl)methanone | 877383-54-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-bromo-2-chlorophenyl)(pyrrolidin-1-yl)methanone
• 英文别名: 1-(4-bromo-2-chlorobenzoyl)-pyrrolidine；1-[(4-bromo-2-chlorophenyl)carbonyl]pyrrolidine；(4-bromo-2-chlorophenyl)-pyrrolidin-1-ylmethanone
• CAS: 877383-54-5
• 化学式: C₁₁H₁₁BrClNO
• 分子量: 288.571
• InChiKey: UWRWWODDKUHLEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  402.3±35.0 °C(Predicted)
• 密度：
  1.560±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (4-bromo-2-chlorophenyl)(pyrrolidin-1-yl)methanone 在 正丁基锂 、 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 38.42h， 生成 3-[3-chloro-4-(pyrrolidin-1-ylmethyl)phenyl]-3-hydroxycyclobutanecarboxylic acid
  参考文献：
  名称：

  Discovery of Two Clinical Histamine H₃ Receptor Antagonists: trans-N-Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)

  摘要：

  The discovery of two histamine H-3 antagonist clinical candidates is disclosed. The pathway to identification of the two clinical candidates, 6 (PF-03654746) and 7 (PF-03654764) required five hypothesis driven design cycles. The key to success in identifying these clinical candidates was the development of a compound design strategy that leveraged medicinal chemistry knowledge and traditional assays in conjunction with computational and in vitro safety tools. Overall, clinical compounds 6 and 7 exceeded conservative safety margins and possessed optimal pharmacological and pharmacokinetic profiles, thus achieving our initial goal of identifying compounds with fully aligned oral drug attributes, "best-in-class" molecules.

  DOI：

  10.1021/jm200939b
• 作为产物：
  描述：

  四氢吡咯 、 4-溴-2-氯苯甲酸 在 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以81 %的产率得到(4-bromo-2-chlorophenyl)(pyrrolidin-1-yl)methanone
  参考文献：
  名称：

  COMPOUNDS AS LXR AGONISTS

  摘要：

  本发明通常揭示具有LXR（肝X受体）激动活性的化合物，用于治疗各种疾病，例如增生性疾病、阿尔茨海默病、炎症性疾病以及胆固醇和脂质代谢缺陷所表征的疾病。具体而言，本发明揭示了式（IA）的化合物，其表现为LXR激动剂活性，特别是LXRβ。本发明还揭示了所述化合物的合成方法、使用方法、包含所述化合物的药物组合物和使用方法。

  公开号：

  US20220363662A1

文献信息

• [EN] BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE<br/>[FR] DÉRIVÉS DE L'ACIDE DIPHÉNOXYACÉTIQUE EMPLOYÉS DANS LE TRAITEMENT DE MALADIES RESPIRATOIRES
  申请人：ASTRAZENECA AB

  公开号：WO2006021759A1

  公开（公告）日：2006-03-02

  The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1, as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

  这项发明涉及到式(I)的取代苯氧乙酸，其中变量如权利要求书中所定义，作为治疗呼吸系统疾病的有用药物化合物，包含它们的药物组合物，以及它们的制备方法。
• HISTAMINE-3 RECEPTOR ANTAGONISTS
  申请人：Wager T. Travis

  公开号：US20080096955A1

  公开（公告）日：2008-04-24

  This invention is directed to a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a process of preparation of a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  本发明涉及一种式I的化合物，如本文所定义，或其药学上可接受的盐；包含式I化合物的制药组合物；制备式I化合物的方法；一种治疗通过拮抗组胺H3受体可治疗的紊乱或病症的方法，该方法包括向需要此类治疗的哺乳动物投与上述式I化合物；以及治疗所选组中的紊乱或病症的方法，所选组包括抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷多动障碍（ADHD）、精神病性疾病、认知障碍、睡眠障碍、肥胖症、头晕、癫痫、晕动病、呼吸系统疾病、过敏、过敏性气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低运动和酸性分泌，该方法包括向需要此类治疗的哺乳动物投与上述式I化合物。
• Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease
  申请人：Luker Timothy Jon

  公开号：US20080132480A1

  公开（公告）日：2008-06-05

  The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1 , as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

  本发明涉及式(I)的取代苯氧基乙酸，其中变量如权利要求书1所定义，作为治疗呼吸系统疾病的有用药物化合物，以及包含它们的药物组合物和它们的制备方法。
• Histamine-3 receptor antagonists
  申请人：Pfizer Inc.

  公开号：US08158673B2

  公开（公告）日：2012-04-17

  This invention is directed to a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a process of preparation of a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  本发明涉及一种公式I的化合物，如本文所定义，或其药学上可接受的盐；包含公式I化合物的制药组合物；制备公式I化合物的方法；一种治疗通过拮抗组胺H3受体可治疗的疾病或症状的方法，该方法包括向需要此类治疗的哺乳动物注射上述的公式I化合物；以及一种治疗从以下疾病或症状中选择的疾病或症状的方法，包括抑郁症、情感障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷多动障碍（ADHD）、精神病性疾病、认知障碍、睡眠障碍、肥胖症、头晕、癫痫、晕动病、呼吸系统疾病、过敏、过敏性气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低动力和酸性分泌，该方法包括向需要此类治疗的哺乳动物注射上述的公式I化合物。
• Histamine-3 Receptor Antagonists
  申请人：Wager Travis T.

  公开号：US20120220568A1

  公开（公告）日：2012-08-30

  This invention is directed to a compound of formula I, wherein R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 and n are as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a process of preparation of a compound of formula I, a method of treatment of a disorder or condition such as depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  本发明涉及一种式子为I的化合物，其中R1、R2、R4、R5、R6、R7、R8和n如此定义，或其药学上可接受的盐；一种含有式I化合物的制药组合物，一种制备式I化合物的方法，一种治疗抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷多动障碍（ADHD）、精神病性疾病、认知障碍、睡眠障碍、肥胖症、头晕、癫痫、晕动病、呼吸系统疾病、过敏、过敏诱发的气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、消化道疾病、胃肠道高低动力和酸性分泌物疾病的方法，该方法包括向需要此类治疗的哺乳动物给予上述式I化合物。